Cisplatin

Generic Name: Cisplatin

Brand Names: Platinol

Drug Type: Small Molecule

Chemical Formula: Cl_₂H_₆N_₂Pt

CAS Number: 15663-27-1

Unique Ingredient Identifier: Q20Q21Q62J

Background: Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.

Indication: For the treatment of metastatic testicular tumors, metastatic ovarian tumors and advanced bladder cancer.

Associated Conditions: Advanced Ovarian Cancer, Ovarian Cancer Metastatic, Advanced Bladder cancer, Advanced Testicular cancer, Metastatic Testicular cancer

Clinical Trials

Nimotuzumab in Combined With Chemotherapy for Treatment of IVB Stage,Rrecurrent or Persistent Cervical Carcinoma

Phase 3

Completed

Conditions: Cervical Squamous Cell Carcinoma
Persistent

Interventions: Drug: Nimotuzumab
Drug: Paclitaxel
Drug: Cisplatin
Drug: Placebo

First Posted Date: 2025-01-17

Last Posted Date: 2025-01-17

Lead Sponsor: Biotech Pharmaceutical Co., Ltd.

Target Recruit Count: 118

Registration Number: NCT06781073

Locations: 🇨🇳
Cancer Institute and Hospital , Chinese Academy of Medical Sciences, Beijing, China

A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Budigalimab in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations

Phase 1

Recruiting

Conditions: Non Small Cell Lung Carcinoma

Interventions: Drug: Pembrolizumab
Drug: Telisotuzumab Adizutecan
Drug: Budigalimab
Drug: Carboplatin
Drug: Pemetrexed
Drug: Cisplatin

First Posted Date: 2025-01-13

Last Posted Date: 2025-05-16

Lead Sponsor: AbbVie

Target Recruit Count: 172

Registration Number: NCT06772623

Locations: 🇺🇸
Providence - St. Jude Medical Center /ID# 271414, Fullerton, California, United States
🇺🇸
FOMAT Medical Research - Clinica mi Salud by Focil Med /ID# 274450, Oxnard, California, United States
🇺🇸
Mid Florida Hematology And Oncology Center /ID# 273777, Orange City, Florida, United States

and more 17 locations

Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial

Phase 2

Recruiting

Conditions: Non-Muscle Invasive Bladder Urothelial Carcinoma
Stage I Bladder Cancer AJCC v8
Recurrent Non-Muscle Invasive Bladder Urothelial Carcinoma

Interventions: Procedure: Biospecimen Collection
Drug: Cisplatin
Procedure: Computed Tomography
Drug: Fluorouracil
Biological: Pembrolizumab
Drug: Gemcitabine
Procedure: Magnetic Resonance Imaging
Drug: Mitomycin
Other: Questionnaire Administration
Radiation: Radiation Therapy

First Posted Date: 2025-01-13

Last Posted Date: 2025-05-16

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 160

Registration Number: NCT06770582

Locations: 🇺🇸
Shaw Cancer Center, Edwards, Colorado, United States
🇺🇸
University of Florida Health Science Center - Gainesville, Gainesville, Florida, United States
🇺🇸
Louisiana Hematology Oncology Associates LLC, Baton Rouge, Louisiana, United States

and more 20 locations

A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer

Phase 3

Recruiting

Conditions: HER2-positive Gastric Cancer
Gastroesophageal Junction Adenocarcinoma

Interventions: Drug: Trastuzumab
Drug: Rilvegostomig
Drug: Trastuzumab deruxtecan
Drug: Pembrolizumab
Drug: 5-fluorouracil
Drug: Capecitabine
Drug: Cisplatin
Drug: Oxaliplatin

First Posted Date: 2025-01-09

Last Posted Date: 2025-04-27

Lead Sponsor: AstraZeneca

Target Recruit Count: 840

Registration Number: NCT06764875

Locations: 🇻🇳
Research Site, Vinh, Vietnam

Neoadjuvant Immunochemotherapy and Chemoradiotherapy Followed by Surgery for Advanced Esophageal Squamous Cell Carcinoma

Phase 2

Not yet recruiting

Conditions: ESCC
Total Neoadjuvant Treatment
Pathological Complete Response

Interventions: Drug: Tislelizumab
Drug: Paclitaxel
Drug: Cisplatin
Radiation: Chemoradiotherapy

First Posted Date: 2025-01-08

Last Posted Date: 2025-01-08

Lead Sponsor: National Taiwan University Hospital

Target Recruit Count: 50

Registration Number: NCT06764355

QL1706 (IPD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma.

Phase 3

Recruiting

Conditions: Nasopharyngeal Cancinoma (NPC)
Nasopharyngeal Cancer

Interventions: Drug: QL1706
Drug: Gemcitabine
Drug: Cisplatin
Radiation: Intensity-modulated radiotherapy

First Posted Date: 2024-12-27

Last Posted Date: 2024-12-27

Lead Sponsor: Sun Yat-sen University

Target Recruit Count: 580

Registration Number: NCT06749899

Prospective Trial Assessing Real World Outcomes Response to Pembro in Black Patients w/ NSCLC

Phase 2

Recruiting

Conditions: Non-small Cell Lung Cancer

Interventions: Drug: Cisplatin
Drug: Carboplatin
Drug: Pemetrexed
Drug: Pembrolizumab
Drug: Abraxane
Drug: Paclitaxel

First Posted Date: 2024-12-20

Last Posted Date: 2025-05-06

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 318

Registration Number: NCT06745882

Locations: 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States

Low-dose Radiotherapy Combined with Concurrent Chemotherapy, Toripalimab and Tifcemalimab in the Treatment of ES-SCLC

Phase 1

Not yet recruiting

Conditions: Extensive-stage Small-cell Lung Cancer

Interventions: Radiation: Low-dose radiotherapy
Drug: Tifcemalimab injection
Drug: Toripalimab
Drug: Cisplatin
Drug: Carboplatin
Drug: Etoposide

First Posted Date: 2024-12-13

Last Posted Date: 2024-12-27

Lead Sponsor: Sichuan University

Target Recruit Count: 12

Registration Number: NCT06732258

First-line Treatment With RC48 Plus Sintilimab and S-1 in Advanced Gastric Cancer (RCTS2)

Phase 2

Recruiting

Conditions: HER2-positive Gastric Cancer
Metastatic Gastric Cancer
Unresectable Gastric Carcinoma

Interventions: Drug: Disitamab Vedotin
Drug: Sintilimab
Drug: Trastuzumab
Drug: Oxaliplatin
Drug: S-1
Drug: Capecitabine
Drug: 5-FU
Drug: Cisplatin

First Posted Date: 2024-12-12

Last Posted Date: 2024-12-31

Lead Sponsor: Qilu Hospital of Shandong University

Target Recruit Count: 110

Registration Number: NCT06730373

Locations: 🇨🇳
Shandong Univerisity Qilu Hospital, Jinan, Shandong, China
🇨🇳
The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
🇨🇳
Jinan Third People's Hospital, Jinan, Shandong, China

and more 17 locations

Intra-arterial Chemotherapy Combined with Radiotherapy and Immunotherapy for HNSCC

Phase 2

Recruiting

Conditions: Head and Neck Squamous Cell Carcinoma

Interventions: Drug: Tislelizumab-jsgr
Drug: Cisplatin
Drug: Albumin-Bound Paclitaxel
Radiation: Radiotherapy

First Posted Date: 2024-12-10

Last Posted Date: 2024-12-10

Lead Sponsor: Beijing Tongren Hospital

Target Recruit Count: 50

Registration Number: NCT06725498

Locations: 🇨🇳
Beijing Tongren Hospital Affiliated to Capital Medical University, Beijing, Beijing, China

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy